Anzeige
Mehr »
Montag, 29.12.2025 - Börsentäglich über 12.000 News
Insider-Alarm bei FUTR: Scott Paterson kauft wie ein Besessener!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
28 Leser
Artikel bewerten:
(0)

United States Market Report for Hemostasis Devices 2017: Hemostasis Probes, Ligation Devices, Sclerotherapy Needles and Electrosurgical Generators - Research and Markets

DUBLIN, November 4, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "US Market Report for Hemostasis Devices 2017 - MedCore" report to their offering.

The value of the total U.S. market for hemostasis devices increased in 2016. Growth is expected to persist throughout the forecasted period and will be driven by increases in unit sales countered by a decrease in the ASP. The vast majority of units in this market are sold to hospitals, with only relatively few units used in the outpatient centers. The four segments have different growth profiles with ligation devices exhibiting low-single digit rate cannibalizing into other segment, and thus resulting in a negative trend within the hemostasis probe segment.

The ESU segment remains relatively flat, as this is mainly the replacement market as of 2016. The needle segment is growing at 1% annually as physicians use it as part of the combination therapy. The major contributor to the unit growth in this market is ligation device segment due to high volume coupled with the low-single digit growth rate.

The U.S. market for hemostasis devices is defined in this report as hemostasis probes, ligation devices, sclerotherapy needles and electrosurgical generators. The largest segment in this market was ligation devices. This segment represented approximately 66.1% of the total market in 2016. The relatively large size of this segment is mainly due to these devices being used as both a stand-alone and combination therapy with other devices to address gastrointestinal (GI) bleeding.

Also, several units of clips are often used during one procedure. The smallest segment in this market was electro surgical generators (ESUs) due to the longevity of this capital equipment that extends beyond ten years, only one unit required per room, and 100% penetration, all resulting in a lower annual sale volume. Most of the devices discussed in this chapter are single-use, except for reusable heat probes and capital equipment, electro surgical generators including argon modules.

Key Topics Covered:

1. U.S. Gastrointestinal Endoscopic Device Market Overview

Competitive Analysis

Market Trends

Market Developments

Procedure Numbers

Procedure Codes Investigated

Markets Included

1.1 Key Report Updates

Version History

Research Methodology

1.1 Research Scope

2. Disease Overview

2.1 Basic Anatomy

2.2 Gastrointestinal Disease: Treatment And Diagnostics

2.2.1 Gastro-Esophageal Reflux Disease (GERD)

2.2.2 Barrett's Esophagus

2.2.3 Digestive Cancer

2.2.4 Gastrointestinal Bleeding

2.2.5 Bile Duct Disorders

2.2.6 Crohn's Disease

2.2.7 Ulcer

2.2.8 Ogilvie Syndrome Or Intestinal Pseudo-Obstruction

2.3 Patient Demographics

2.3.11 Patient Demographics

2.3.11.1 All Digestive Diseases

2.3.11.2 Abdominal Wall Hernia

2.3.11.3 Chronic Constipation

2.3.11.4 Diverticular Disease

2.3.11.5 Prescriptions

2.3.11.6 Gastroesophageal Reflux Disease

2.3.11.7 Gastrointestinal Infections

2.3.11.8 Hemorrhoids

2.3.11.9 Inflammatory Bowel Disease

2.3.11.10 Liver Disease

2.3.11.11 Pancreatitis

2.3.11.12 Peptic Ulcer Diseases

2.3.12 Digestive Cancer

3. Product Assessment

3.1 Product Portfolios

3.1.1 Hemostasis Devices

3.1.1.1 Introduction

3.1.1.1.1 Product Matrix For Hemostasis Devices

3.2 Regulatory Issues And Recalls

3.2.1 Hemostasis Devices

3.3 Clinical Trials

3.3.1 Hemostasis Devices

3.4 Product Pipelines

3.4.1 Boston Scientific

3.4.1.1 Axios Stent And Electrocautery Enhanced Delivery System

3.4.1.2 Acquire Endoscopic Ultrasound Fine Needle Biopsy (Fnb) Device

3.4.1.3 Safe Enteral Feeding Product

3.4.1.4 Rotatable Snare

3.4.2 Cook Inc.

3.4.2.1 Lehman Manometry Catheter

3.4.3 Olympus

3.4.3.1 Olympus Ez Shot 3 Plus - A Single-Use Aspiration Needle

3.4.3.2 Olympus Esg-200 Electrosurgical Generator

3.4.3.3 Retooled Gi Benchmarking Service

3.4.3.4 Big Screen Surgery In 4K: Visera 4K Uhd System

3.4.3.5 Tjf-Q180V Duodenoscope

3.4.3.6 From Ar 2015 - New Strategy Plan For General Surgery Unit

3.4.4 Medtronic / Covidien

3.4.4.1 Safe Enteral Feeding Product Line 2016

3.4.4.2 Barrx 360 Express Rfa Balloon Catheter For Barrett's Esophagus

3.4.5 Avantis Medical Systems

3.4.5.1 Third Eye Panoramic Colonoscopy Device

3.4.6 Pentax Medical/ Hoya

3.4.6.1 H Optivista-Epk-I7010 Video Processor For Endoscopy

3.4.7 Fujifilm

3.4.7.1 Sonart Su-1 Endoscopic Ultrasonic Processors

3.4.7.2 Double Balloon Endoscope (En-580T)

3.4.8 Us Endoscopy

3.4.8.1 Moray® Micro Forceps

3.4.9 Conmed Corporation

3.4.9.1 Abc D-Flex Probes

3.4.10 Endochoice

3.4.10.1 Fda Clearance For Orca Sterile, Single-Use Air/Water And Suction Valves

3.4.10.2 Third Generation Fuse® Full Spectrum Endoscopy® System

3.4.10.3 Rescuenet Retrieval Device

3.4.10.4 Lumos Adaptive Matrix Imaging System

3.4.11 Endogastric Solution

3.4.11.1 Next-Generation Version Of Esophyx® Device - Esophyx® Z

3.4.12 Mederi Therapeutics

3.4.12.1 Stretta Rft3 Technology

3.4.13 C2 Therapeutics

3.4.13.1 Coldplay Iii Trial Validating The C2 Cryoballoon Focal Ablation System For Treating Barret'S Esophagus

3.4.14 Medigus

3.4.14.1 Next Generation Muse System For The Long-Term Treatment Of GERD

3.4.15 Merit Medical Systems, Inc.

3.4.15.1 Corvocet Biopsy System

3.4.16 Medivators, Inc.

3.4.16.1 Amplifeye Endoscopic Overtube

3.4.17 Fujifilm Medical Systems Usa, Inc.

3.4.17.1 Fujifilm Diathermic Slitter (Flushknife) And Fujifilm Diathermic Slitter (Clutchcutter)

3.4.17.2 New Additions For Double Balloon Endoscopy (Dbe) Platform And The Advanced Endoscopic Platform Including Flushknife And Clutchcutter

3.4.18 Cook Medical

3.4.18.1 New Study A Multicenter Trial, Comparing A 25G Eus Fine Needle Aspiration (Fna) Device With A 20G Eus Procore Fine Needle Biopsy (Fnb) Device (Aspro)

3.4.19 Vital Images, Inc.

3.4.19.1 Vitrea Ct Colon Analysis

4. Hemostasis Device Market

4.1 Market Overview

4.2 Market Analysis And Forecast

4.2.1 Total Hemostasis Device Market

4.2.2 Total Hemostasis Probe Market

4.2.2.1 Total Electrosurgical Probe Market

4.2.2.1.1 Conventional Electrosurgical Probe Market

4.2.2.1.2 Injection-Needle Probe Market

4.2.2.2 Heat Probe Market

4.2.2.3 Argon Plasma Coagulation Probe Market

4.2.3 Ligation Device Market

4.2.3.1 Ligation Band Market

4.2.3.2 Ligation Clip Market

4.2.4 Sclerotherapy Needle Market

4.2.5 Electrosurgical Generator Market

4.2.6.1 Electrosurgical Unit Market

4.2.7.1 Argon Module Market

4.3 Drivers And Limiters

4.3.1 Market Drivers

4.3.2 Market Limiters

4.4 Competitive Market Share Analysis

For more information about this report visit http://www.researchandmarkets.com/research/wng999/us_market_report

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

© 2016 PR Newswire
Gold & Silber auf Rekordjagd
Kaum eine Entwicklung war 2025 so eindrucksvoll wie der Höhenflug der Edelmetalle. Allen voran Silber: Angetrieben von einem strukturellen Angebotsdefizit, explodierte der Preis und übertrumpfte dabei den „großen Bruder“ Gold. Die Nachfrage aus dem Investmentsektor zieht weiter an, und ein Preisziel von 100 US-Dollar rückt in greifbare Nähe.

Auch Gold markierte neue Meilensteine. Mit dem Durchbruch über 3.000 und 4.000 US-Dollar pro Unze hat sich der übergeordnete Aufwärtstrend eindrucksvoll bestätigt. Rücksetzer bleiben möglich, doch der nächste Zielbereich bei 5.000 US-Dollar ist charttechnisch fest im Blick. Die fundamentalen Treiber sind intakt, eine nachhaltige Trendwende aktuell nicht in Sicht.

Für Anlegerinnen und Anleger bedeutet das: Jetzt ist die Zeit, um gezielt auf starke Produzenten zu setzen. In unserem neuen Spezialreport stellen wir fünf Gold- und Silberaktien vor, die trotz Rallye weiter attraktives Potenzial bieten, mit robusten Fundamentaldaten und starken Projekten in aussichtsreichen Regionen.

Jetzt den kostenlosen Report sichern und von der nächsten Welle im Edelmetall-Boom profitieren!

Dieses exklusive PDF ist nur für kurze Zeit verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.